glp 1 approved for cardiovascular disease GLP-1 Agonists in Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies GLP-1RAs reduce cardiovascular deaths in

For instance, a key element in the innate immune response is the inflammation mediated by Toll-like receptors

Tram NK McLean RM and Swindle-Reilly KE

Tumor metastasis: Molecular insights and evolving paradigms

Natriuretic peptides in chronic kidney disease and during renal replacement therapy: an update

The clinical uptake of biomarkers for diagnosing HFpEF has generally been poor, with only cardiac natriuretic peptides (NPs) having emerged as clinically relevant.1 Indeed, current European Society of Cardiology (ESC)/Heart Failure Association guidelines provide a class IB recommendation for NPs for diagnosis of suspected HF and NPs are a major criterion for establishing the diagnosis of HFpEF.1 In this review we discuss identified HFpEF biomarkers derived from different pathological pathways

Science 373 , 9981004 (2021)